Live Markets
Tuesday, July 28, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

Becton, Dickinson and Company (BDX)

NYQ · Medical Instruments & Supplies

$166.34+7.42 (+4.67%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$45.83B
P/E (TTM)
27.72
EPS
$6.00
Div Yield
2.64%
52W Range
$127.59–$187.35
Beta
0.27

Company overview

Next earnings: 2026-08-06(9d)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Peers in Medical Instruments & Supplies

All in industry →

Recent press releases

April 2026

3 months ago8-KHealthcare

BDX Executive Vice President Byrd to Retire, Successor Planned

BDXBECTON DICKINSON & CO

# 🧾 What This Document Is This is a **Form 8-K**, a "current report" that companies must file with the SEC to announce major events that shareholders should know about. Think of it as a quick, important news alert. This specific report has two main announcements: an executive retirement and a relat

Read summaryView on SEC EDGAR

SEC filings

All filings →
1 recent filing shown in the timeline above. View all SEC filings →

Becton, Dickinson and Company has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30
13,362,155 sh● NEW
36,678,939 sh+13.0%
3,493,618 sh-33.9%
1,457,212 sh+39252.2%
644,135 sh-66.9%
3,790,490 sh+48.5%
5,472,003 sh-21.2%

People at Becton, Dickinson and Company

All people →

Quarterly financials

Full financials →
Revenue trend
12/24
$418.0M
NI $303.0M
03/25
$323.0M
NI $308.0M
06/25
$714.0M
NI $574.0M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $2.00
Prior: $1.07
Revenue sparkline